NATIONAL GUARD BUREAU (NGB) GUIDELINES FOR MANAGEMENT

File: aabhc_01.txt
Page: 01
Total Pages: 2
SUBJECT:  NATIONAL GUARD BUREAU (NGB) GUIDELINES FOR MANAGEMENT
                   OF NERVE AGENT CASUAL TGIES AT CENTAF FACILITIES
    
IMMEDIATE
    
                                                   UNCLASS I F I ED
    
                                     BASE COMMUNICATIONS CENTER
                                             390 COSQ/DONA 
    
PAGE 01 OF 02                                                                                                               20/0418Z
STRATEGIC AIR COMMAND                                                                     (UNIT TOTAL:  008)                          
OPR: CG(02) CS(03) SG(03)
          
INFO: FILE COPY(01) SENIOR CONTROLLER (TUBE) (01)
    
                                                    ------------------------- 20/0425Z A2    14   (TOTAL COPIES: 010)
OATUZYUW RHDJGAA0782 2630415-UUUU--RUCUAAA.
ZNR UUUUU
O 191702Z SEP 90
FM NGB ANDREWS AFB MD//CSS//
TO AIG 7301//CC//SG.
AIG 7311//CC//SG//
RUCIRMA/109AEF MINNEAPOLIS ST PAUL IAP MN//CC//
RUVRBMA/ 118AES NASHVILLE IAP TN//SG//
RUVOBJA/ 137AEF WILL ROGERS WORLD APRT OKLAHOMA CITY
OK//SG/SGNI//
RUVABIA/ 139AEF STRATTON ANGB SCOTIA NY//DOCM//
RUVABOA/ 142AEF MCCA NEW CASTLE DE//DOCM//
RUWFPAA/146AES CHANNEL ISLANDS ANGB CA//SGA//
RUVRBIA/ 156AEF CHARLOTTE DOUGLAS IAP NC//CC//
RUVRPA/ 167AEF EWVRA SHEPPARD FLD MARTINSBURG WV//SGO//
RUVRBGA/ 183AEF ALLEN C THOMPSON FLD MS//SG//
RUVHBKA/ 187AEF CHEYENNE MUNI APRT WY//SGO//
ACCT AF-ACXJRF
ZEN 113TFW ANDREWS AFB MD//SG//
ZEN NGS ANDREWS AFB MD//SGAX//SGP//
INFO ZEN ANDREWS AFO MD//SGP//
BT
UNCLAS
QQQQ
UBJ: GUIDELINES FOR MANAGEMENT OF NERVE AGENT CASULTIES AT CENTAF
2E FACILITIES. .
USCENTAF TAC LANGLEY AFB VA/BSD MSG 121601Z SEP 90 IS FORWARDED FOR
YOUR INFORMATION. QUOTE:
1. THE FOLLOWING SUBJECT GUIDELINES HAVE BEEN JOINTLY DEVELOPED BY
HO USAF/SGHR AND HO TACOPS/SGPA.  A FLOW SHEET FOR QUICK REFERENCE IS
ALSO BEING DEVELOPED.
A. TRIAGE
(1) IMMEDIATE
(A) RESPIRATORY DISTRESS
(B) CONVULSIONS
(C) LOSS OF CONSCIOUSNESS
(D) OBSTRUCTIVE AIRWAY SECRETIONS
(E) CYANOSIS
(2) DELAYED
(A) PROFUSE ORAL/'PHARYNGEAL SECRETIONS WITHOUT SIGNS OR SYMPTOMS OF
AIRWAY OBSTRUCTION.
(B) MUSCLE TWITCHING/FASCICULATIONS WITH OR WITHOUT WEAKNESS.
(C) PATIENTS WITH LESS THAN IMMEDIATE SYMPTOMS WHO HAVE BEEN
PREVIOUSLY ADMINISTERED ALL THREE ATROPINE AUTOINJECTORS.
(3) MINIMAL
(A) SYMPTOMS RESOLVED ON 1 OR 2 ATROPINE AUTOINJECTORS
(B) NASAL CONGESTION
(C) EYE PAIN, BLURRED, OR DIM VISION
(D) RETROBULBAR HEADACHE
(E) NAUSEA
(F) MILD CHEST TIGHTNESS
(G) EXPECTANT
(A) CHEMICAL AGENT EXPOSURE IN A PATIENT WITH EXPECTANT CONVENTIONAL
INJURY
B. TREATMENT
(1) IMMEDIATE
(A) INSURE ALL AUTOINJECTORS (3 ATROPINE- 3 PRALIDOXIME) HAVE ALREADY
BEEN GIVEN
(B) INSURE DIAZEPAM 2 ML (10 MG) OR 1 AUTOINJECTOR HAS BEEN GIVEN.
(C) ATROPINE 1 ML (2 MG) IM EVERY 2-4 MIN
(D) IF CONVULSING, DIAZEPAM (VALIUM) 2 ML (10 MG) DEEP IM
(E) AIRWAY (CONTINUED ATROPINE ADMINISTRATION IS CRITICAL TO AIRWAY
MANAGE MENT)
(F) SUCTION
(G) ASSISTED VENTILATION (MAY ONLY BE REQUIRED FOR A SHORT TIME)
    
                                                       UNCLASSIFIED